How Does Drug Rescheduling Work, and What Would It Mean for Psychedelics?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Anyone who has read about psilocybin rescheduling, cannabis rescheduling, or MDMA’s path to approval and wants to understand what “rescheduling” actually means legally — how the process works, who decides, and what would change if a psychedelic moved from Schedule I to a lower schedule.

The short answer

Drug rescheduling is a federal administrative process governed by 21 U.S.C. § 811 of the Controlled Substances Act. It is the mechanism by which a substance moves between the five federal drug schedules — or gets removed from scheduling entirely. The process requires a scientific and medical evaluation from the Department of Health and Human Services, a notice-and-comment rulemaking by the DEA, and in contested cases, an administrative hearing. It does not happen quickly, it does not happen automatically, and the fact that it is underway for a substance does not mean it will succeed or that the outcome is predetermined. For psychedelics, rescheduling is the legal bridge between Schedule I prohibition and any form of legitimate prescribable access — but crossing it involves years of administrative procedure, not a single announcement.

What the schedules are and why they matter

The Controlled Substances Act divides regulated substances into five schedules based on three criteria: potential for abuse, currently accepted medical use in the United States, and accepted safety for use under medical supervision. Schedule I is reserved for substances that, in the federal government’s determination, meet all three of the following conditions: high potential for abuse, no currently accepted medical use in treatment in the United States, and no accepted safety even under medical supervision.

The practical consequence of Schedule I status is absolute prohibition: no prescriptions, no dispensing, no clinical administration outside a DEA-authorized research framework. Schedule II through V each require a currently accepted medical use, which is why they can be prescribed. Schedule II substances carry the highest restrictions within that prescribable range — they require written prescriptions with no refills — while Schedules III through V carry progressively fewer restrictions.

Moving a substance from Schedule I to Schedule II or lower does not legalize it in any general sense. It removes the bar on prescribing and reduces some research restrictions, but the substance remains federally controlled. Possession without authorization remains illegal. Manufacturing and distribution outside licensed channels remain illegal.

How rescheduling is initiated

Under 21 U.S.C. § 811(a), proceedings to reschedule a substance may be initiated by three parties: the DEA acting on its own authority, the Department of Health and Human Services, or any interested party through a formal petition. “Interested party” is broad — it includes drug manufacturers, medical associations, pharmacy associations, individual physicians, public interest groups, and state or local government agencies.

Once a petition is received, the DEA begins its own investigation and then, before it can take any rulemaking action, must request from HHS a scientific and medical evaluation of the substance and HHS’s recommendation on scheduling.

The role of HHS and why its findings are binding

HHS — acting through the FDA and informed by the National Institute on Drug Abuse — evaluates the substance against an eight-factor analysis drawn from 21 U.S.C. § 811(c). The eight factors are: actual or relative potential for abuse; scientific evidence of pharmacological effects; the state of current scientific knowledge; history and current pattern of abuse; scope, duration, and significance of abuse; risk to public health; psychological or physiological dependence liability; and whether the substance is an immediate precursor of an already-controlled substance.

HHS’s scientific and medical determinations are binding on the DEA. Under 21 U.S.C. § 811(b), if HHS recommends that a substance not be controlled at all, the DEA is legally prohibited from controlling it. The DEA may conduct its own investigation, but it cannot contradict HHS’s scientific conclusions on the medical use and safety questions. The DEA retains authority over the non-scientific aspects of the scheduling decision — including abuse potential assessments beyond the medical use question — and makes the final decision on whether to propose rescheduling and into which schedule.

The rulemaking process after HHS acts

Once HHS delivers its recommendation, the DEA evaluates the full record and decides whether to publish a Notice of Proposed Rulemaking in the Federal Register. That notice initiates the formal public comment period, during which any party — including industry, researchers, advocacy organizations, state governments, and individuals — may submit written comments. Under the CSA, any interested party may also request a hearing, which converts the proceeding into a more formal administrative process with testimony, evidence, and the opportunity for cross-examination before an Administrative Law Judge.

After the comment period and any hearing, the DEA reviews the record and issues a final rule. That final rule, published in the Federal Register, is the action that actually changes a substance’s schedule. Rulemaking under the CSA qualifies as formal rulemaking, meaning it must satisfy the Administrative Procedure Act’s requirements for an adequate evidentiary record, a reasoned explanation, and a decision that is not arbitrary and capricious. Final rules are subject to judicial review.

This process is not fast. The cannabis rescheduling process, initiated by President Biden’s 2022 directive, had not produced a final rule as of early 2026 — and it benefited from unusual political momentum. A typical administrative rescheduling from petition to final rule takes multiple years.

What would actually change if psilocybin were rescheduled

From Schedule I to Schedule II. Psilocybin could be prescribed by licensed physicians for approved indications. DEA registration requirements would change — Schedule II researcher registrations differ from Schedule I researcher registrations, and the supply chain controls, quota systems, and record-keeping requirements would shift accordingly. Section 280E of the Internal Revenue Code, which prevents state-licensed cannabis businesses from deducting ordinary business expenses, would no longer apply to psilocybin businesses, since 280E only applies to substances in Schedules I and II of the CSA. Research would become somewhat easier, as the barriers specific to Schedule I — particularly the DEA production quotas that limit available research supply — would be reduced.

From Schedule I to Schedule III or lower. The same prescribing authorization would apply. The research restrictions would be even more relaxed than under Schedule II. The 280E consequences would not apply. Schedule III substances can be prescribed with refills, unlike Schedule II.

What would not change. Rescheduling does not federally legalize a substance for general use. It does not authorize manufacture, possession, or sale outside licensed and regulated channels. State law would still need to accommodate the newly rescheduled status — in some states, changes in federal schedule automatically trigger a corresponding change under state law, while others require independent legislative or regulatory action. Rescheduling would not create an immediate access pathway; an FDA-approved drug product would still need to exist before prescribing could occur, unless the rescheduling were tied to or followed by such approval.

Where psilocybin rescheduling currently stands

On August 11, 2025, the DEA formally transmitted a rescheduling petition for psilocybin to HHS for scientific and medical evaluation. The petition was filed by Dr. Sunil Aggarwal of the Advanced Integrated Medical Science (AIMS) Institute, who has sought to administer psilocybin to terminally ill patients since at least 2020. The petition reached HHS after years of legal battles, including a Ninth Circuit ruling that directed the DEA to reconsider its earlier denial.

HHS is now conducting the required scientific and medical evaluation. When HHS completes its evaluation, it will transmit a recommendation to the DEA. The DEA will then decide whether to initiate rulemaking. No timeline has been established, and there is no automatic outcome. The petition asks for rescheduling to Schedule II. Some commentators have suggested psilocybin’s pharmacological profile is closer to Schedule III, given its relatively low dependence liability compared to Schedule II substances like opioids and stimulants.

As of March 2026, psilocybin remains Schedule I. The rescheduling process is underway — at HHS — but has not produced a proposed rule, a notice-and-comment period, a hearing, or a final rule.

How cannabis rescheduling parallels and differs

Cannabis rescheduling has traveled further through the process and offers the closest available parallel for understanding how the psilocybin petition might proceed. In October 2022, President Biden directed HHS and the DEA to review cannabis scheduling. HHS recommended rescheduling to Schedule III in August 2023. The DEA published a proposed rule in May 2024. The public comment period generated approximately 43,000 comments. An administrative hearing was scheduled for January 2025, then stayed due to procedural disputes. President Trump issued an executive order in December 2025 directing the DEA to complete the rulemaking as expeditiously as law permits. As of early 2026, the final rule had not been issued and cannabis remained Schedule I.

The parallel reinforces one structural point: even a rescheduling process with significant political support, a binding HHS recommendation, a published proposed rule, and a presidential executive order still took more than three years without producing a final rule.

Common mistakes and misconceptions

“The DEA forwarded the psilocybin petition, so rescheduling is happening.” The DEA’s August 2025 transmittal to HHS is a required procedural step, not a decision. HHS still needs to complete its scientific evaluation, transmit a recommendation, and the DEA must then decide whether to initiate rulemaking. Many petitions proceed no further.

“If HHS recommends rescheduling, the DEA has to do it.” HHS’s scientific and medical findings are binding on the DEA — particularly the conclusion about currently accepted medical use. But the DEA retains authority over other aspects of the scheduling analysis and makes the final rulemaking decision. The DEA could accept HHS’s medical findings while reaching different conclusions on other scheduling criteria, though such a deviation would invite legal challenge.

“Rescheduling would make psilocybin legal.” Rescheduling removes the bar on prescribing and reduces some research restrictions. General possession, manufacture, and sale outside licensed channels would remain federal crimes.

“Rescheduling is the same as FDA approval.” These are separate processes on separate tracks. FDA approval establishes that a specific drug product is safe and effective for a specific indication. Rescheduling changes a substance’s classification under the CSA. They interact — FDA approval typically triggers a mandatory DEA scheduling review under 21 U.S.C. § 811(j) — but neither requires the other. Psilocybin could theoretically be rescheduled through the petition pathway without any FDA-approved drug product existing, though that would leave the question of what licensed prescribers could actually prescribe.

When you should speak with a lawyer

You should speak with a lawyer if:

You operate a business handling psilocybin or other Schedule I substances and want to understand how rescheduling could affect your tax treatment, licensing, or compliance obligations
You are a researcher working with Schedule I psychedelics and want to understand how rescheduling would change your DEA registration and research authorization
You are tracking the psilocybin or cannabis rescheduling process and want to understand the legal significance of each procedural development
You are building a psychedelic business and need to understand the legal situation that rescheduling would create versus the one that currently exists

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.